Menu
GWAS Study

Correlates of suicidal behaviors and genetic risk among United States veterans with schizophrenia or bipolar I disorder.

Bigdeli TB, Barr PB, Rajeevan N et al.

38491344 PubMed ID
GWAS Study Type
5334 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

BT
Bigdeli TB
BP
Barr PB
RN
Rajeevan N
GD
Graham DP
LY
Li Y
MJ
Meyers JL
GB
Gorman BR
PR
Peterson RE
SF
Sayward F
RK
Radhakrishnan K
NS
Natarajan S
ND
Nielsen DA
WA
Wilkinson AV
MA
Malhotra AK
ZH
Zhao H
BM
Brophy M
SY
Shi Y
OT
O'Leary TJ
GT
Gleason T
PR
Przygodzki R
PS
Pyarajan S
MS
Muralidhar S
GJ
Gaziano JM
HG
Huang GD
CJ
Concato J
SL
Siever LJ
DL
DeLisi LE
KN
Kimbrel NA
BJ
Beckham JC
SA
Swann AC
KT
Kosten TR
FA
Fanous AH
AM
Aslan M
HP
Harvey PD
Chapter II

Abstract

Summary of the research findings

Persons diagnosed with schizophrenia (SCZ) or bipolar I disorder (BPI) are at high risk for self-injurious behavior, suicidal ideation, and suicidal behaviors (SB). Characterizing associations between diagnosed health problems, prior pharmacological treatments, and polygenic scores (PGS) has potential to inform risk stratification. We examined self-reported SB and ideation using the Columbia Suicide Severity Rating Scale (C-SSRS) among 3,942 SCZ and 5,414 BPI patients receiving care within the Veterans Health Administration (VHA). These cross-sectional data were integrated with electronic health records (EHRs), and compared across lifetime diagnoses, treatment histories, follow-up screenings, and mortality data. PGS were constructed using available genomic data for related traits. Genome-wide association studies were performed to identify and prioritize specific loci. Only 20% of the veterans who reported SB had a corroborating ICD-9/10 EHR code. Among those without prior SB, more than 20% reported new-onset SB at follow-up. SB were associated with a range of additional clinical diagnoses, and with treatment with specific classes of psychotropic medications (e.g., antidepressants, antipsychotics, etc.). PGS for externalizing behaviors, smoking initiation, suicide attempt, and major depressive disorder were associated with SB. The GWAS for SB yielded no significant loci. Among individuals with a diagnosed mental illness, self-reported SB were strongly associated with clinical variables across several EHR domains. Analyses point to sequelae of substance-related and psychiatric comorbidities as strong correlates of prior and subsequent SB. Nonetheless, past SB was frequently not documented in health records, underscoring the value of regular screening with direct, in-person assessments, especially among high-risk individuals.

up to 5,334 European ancestry, African American or Afro-Caribbean individuals

Chapter III

Study Statistics

Key metrics and study information

5334
Total Participants
GWAS
Study Type
No
Replicated
European, African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.